Results 21 to 30 of about 23,536 (264)

Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.

European journal of medicinal chemistry, 2020
Inspired by our previous efforts to improve the drug-resistance profiles of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), a novel series of "dual-site" binding diarylpyrimidine (DAPY) derivatives targeting both the NNRTI adjacent site ...
Da Feng, Xiaofang Zuo, Lan-Lan Jing, Chin-Ho Chen, F. Olotu, Hao Lin, M. Soliman, E. De Clercq, C. Pannecouque, Kuo-Hsiung Lee, Dong-Wei Kang, Xin-Yong Liu, Peng Zhan   +12 more
semanticscholar   +1 more source

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.

Journal of Antimicrobial Chemotherapy, 2020
OBJECTIVES Doravirine is a recently licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and safety profile compared with efavirenz and limited cross-resistance with rilpivirine and etravirine.
F. Saladini, Federica Giammarino, Behnaz-Alsadat Hosseini, Alessia Giannini, A. Boccuto, Filippo Dragoni, I. Vicenti, R. Shafer, M. Zazzi   +8 more
semanticscholar   +1 more source

Prevalence and Outcomes of Recycling NNRTIs Despite Documented NNRTI Resistance in HIV-Infected Children and Youth [PDF]

AIDS Patient Care and STDs, 2014
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly used in pediatric patients; however, rapid development of resistance, due to non-adherence and cross-resistance, results in their discontinuation and limits their recycling. We evaluated the clinical experience of recycling NNRTIs despite documented NNRTI resistance (NNRTI-R), and ...
Allison L, Agwu, Jennifer Y, Chang, Ryan E, Wiegand, John T, Wheeling, Beverly A, Bohannon, Kenneth L, Dominguez   +5 more
openaire   +2 more sources

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study

Журнал инфектологии, 2018
A randomized multicenter 96-week study of an elsulfavirine (ESV),  non-nucleoside reverse transcriptase inhibitor (NNRTI) of novel  generation, in combination with 2 nucleoside/ nucleotide reverse  transcriptase inhibitors (NRTIs) was conducted in naive ...
A. V. Kravchenko, E. A. Orlova-Morozova, T. E. Shimonova, O. A. Kozyrev, F. I. Nagimova, N. G. Zaharova, E. S. Ivanova, U. A. Kuimova, A. A. Popova, O. E. Chernova, O. S. Tonkih, D. A. Gusev, A. A. Yakovlev, V. V. Pokrovsky, V. V. Bychko, N. V. Vostokova   +15 more
doaj   +1 more source

Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China

Journal of Global Antimicrobial Resistance, 2023
: Objectives: To assess the virological outcomes, prevalence of HIV drug resistance mutation (DRM), and correlates in Butuo County. Methods: We conducted a cross-sectional study.
Minghong Chen, Min Wu, Liyan Zeng, Yong Zhang, Muzuo Huobu-mo, Juhua Li, Chaoqun Li, Hong Xiao   +7 more
doaj   +1 more source

Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

PLoS ONE, 2013
BackgroundNon-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutants have been shown to emerge after interruption of suppressive NNRTI-based antiretroviral therapy (ART) using routine testing.
Anna Maria Geretti, Zoe Fox, Jeffrey A Johnson, Clare Booth, Jonathan Lipscomb, Lieven J Stuyver, Gilda Tachedjian, John Baxter, Giota Touloumi, Clara Lehmann, Andrew Owen, Andrew Phillips, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group   +12 more
doaj   +1 more source

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

Frontiers in Virology, 2022
The V179I substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in humans or mouse models treated with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Richa Dwivedi, Youya Wang, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose   +4 more
doaj   +1 more source

Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. [PDF]

PLoS ONE, 2013
BACKGROUND:Non-adherence is one of the strongest predictors of therapeutic failure in HIV-positive patients. Virologic failure with subsequent emergence of resistance reduces future treatment options and long-term clinical success.
Viktor von Wyl, Thomas Klimkait, Sabine Yerly, Dunja Nicca, Hansjakob Furrer, Matthias Cavassini, Alexandra Calmy, Enos Bernasconi, Jürg Böni, Vincent Aubert, Huldrych F Günthard, Heiner C Bucher, Tracy R Glass, Swiss HIV Cohort Study   +13 more
doaj   +1 more source

Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity. [PDF]

PLoS ONE, 2014
BACKGROUND: A sensitive, phenotypic reverse transcriptase (RT)-based drug susceptibility assay for the detection of etravirine (ETR) resistance in patient isolates was developed and compared with the results from direct sequencing and ultra-deep ...
Eva Agneskog, Piotr Nowak, Catharina Maijgren Steffensson, Maria Casadellà, Marc Noguera-Julian, Roger Paredes, Clas F R Källander, Anders Sönnerborg   +7 more
doaj   +1 more source

Emergence of an NNRTI Resistance Mutation Y181C in an HIV-Infected NNRTI-Naive Patient

AIDS Research and Human Retroviruses, 2008
The purpose of our study was to examine the emergence of the Y181C resistance mutation in an NNRTI-naive subject (index patient) at different time points. Phylogenetic trees in protease (PR) and partial reverse transcriptase (RT) regions were inferred by the maximum likelihood (ML) method.
Magiorkinis, E., Paraskevis, D., Sambatakou, H., Gargalianos, P., Haida, C., Vassilakis, A., Hatzakis, A.   +6 more
openaire   +3 more sources